Journal Mobile Options
Table of Contents
Vol. 43, No. 2, 2007
Issue release date: February 2007
Pediatr Neurosurg 2007;43:102–106
(DOI:10.1159/000098381)

Expansion Cranioplasty with Jackscrew Distracters for Craniosynostosis and Intracranial Hypertension in Transplanted Osteopetrosis

Dowlati D. · Winston K.R. · Ketch L.L. · Quinones R. · Giller R. · Frattini A. · van Hove J.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: An 11-month-old boy with autosomal recessive infantile osteopetrosis presented, 7 months after bone marrow transplantation, with normal ventricular size and life-threatening intracranial hypertension due to pansynostosis. Methods: The cranial vault was expanded by using jackscrew distracters to upwardly advance the upper part of the calvarium. Results: The procedure achieved a 15-mm upward expansion of the cranial vault over a 15-day period, and the volume of the cranial vault was increased by 139 ml. All clinical manifestations of intracranial hypertension resolved. Conclusion: Cranial vault expansion with jackscrew distracters was successful in relieving intracranial hypertension in an infant with pancraniosynostosis complicating bone marrow transplanted malignant infantile osteopetrosis.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Fasth A, Porras O: Human malignant osteopetrosis: pathophysiology, management and the role of bone marrow transplantation. Pediatr Transplant 1999;3(suppl 1):102–107.
  2. Felix R, Hofstetter W, Cecchini MG: Recent developments in the understanding of the pathophysiology of osteopetrosis. Eur J Endocrinol 1996;134:143–156.
  3. Steward CG: Neurological aspects of osteopetrosis. Neuropathol Appl Neurobiol 2003;29:87–97.
  4. Tolar J, Teitelbaum SL, Orchard PJ: Osteopetrosis. N Engl J Med 2004;351:2839–2849.
  5. Wilson CJ, Vellodi A: Autosomal recessive osteopetrosis: diagnosis, management, and outcome. Arch Dis Child 2000;83:449–452.
  6. Frattini A, Orchard PJ, Sobacchi C, et al: Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis. Nat Genet 2000;25:343–346.
  7. Frattini A, Pangrazio A, Susani L, et al: Chloride channel ClCN7 mutations are responsible for severe recessive, dominant and intermediate osteopetrosis. J Bone Miner Res 2003;18:1740–1747.
  8. Sobacchi C, Frattini A, Orchard PJ, et al: The mutational spectrum of human malignant autosomal recessive osteopetrosis. Hum Mol Genet 2001;10:1767–1773.
  9. Rouselle AV, Heyman D: Osteoclastic acidification pathways during bone resorption. Bone 2002;30:533–540.
  10. Helfrich MH, Aronson DC, Everts V, et al: Morphologic features of bone in human osteopetrosis. Bone 1991;12:411–419.
  11. Beard CJ, Key L, Newburger PE, et al: Neutropil defect associated with malignant infantile osteopetrosis. J Lab Clin Med 1986;108:498–505.
  12. Takai T, Inui M, Inoue K, Mori Y: [Regulation of osteoclast development by immunoglobulin-like receptors]. Nippon Rinsho 2005;63:1562–1568.

    External Resources

  13. Teitelbaum SL: Bone resorption by osteoclasts. Science 2000;289:1504–1508.
  14. Cleiren E, Bénichou O, Van Hul E, et al: Albers-Schönberg disease (autosomal dominant osteopetrosis, type II) results from mutations in the ClCN7 chloride channel gene. Hum Mol Genet 2001;10:2861–2867.
  15. Stocks RM, Wang WC, Thompson JW, Stocks MC 2nd, Horwitz EM: Malignant infantile osteopetrosis: otolaryngological complications and management. Arch Otolaryngol Head Neck Surg 1998;124:689–694.
  16. Taranta A, Migliaccio S, Recchia I, et al: Genotype-phenotype relationship in human ATP6i-dependent autosomal recessive osteopetrosis. Am J Pathol 2003;162:57–68.
  17. Cheow HK, Steward CG, Grier DJ: Imaging of malignant infantile osteopetrosis before and after bone marrow transplantation. Pediatr Radiol 2001;31:869–875.
  18. Coccia PF, Krivit W, Cervenka J, et al: Successful bone-marrow transplantation for infantile malignant osteopetrosis. N Engl J Med 1980;302:701–708.
  19. Gerritsen EJ, Vossen JM, Fasth A, et al: Bone marrow transplantation for autosomal recessive osteopetrosis: a report from the Working Party on Inborn Errors of the European Bone Marrow Transplantation Group. J Pediatr 1994;125:896–902.
  20. Kapelushnik J, Shalev C, Yaniv I, et al: Osteopetrosis: a single centre experience of stem cell transplantation and prenatal diagnosis. Bone Marrow Transplant 2001;27:129–132.
  21. McMahon C, Will A, Hu P, Shah GN, Sly WS, Smith OP: Bone marrow transplantation corrects osteopetrosis in the carbonic anhydrase II deficiency syndrome. Blood 2001;97:1947–1950.
  22. Thompson DA, Kriss A, Taylor D, et al: Early VEP and ERG evidence of visual dysfunction in autosomal recessive osteopetrosis. Neuropediatrics 1998;29:137–144.
  23. Frattini A, Blair HC, Sacco MG, et al: Rescue of ATPa3-deficient murine malignant osteopetrosis by hematopoietic stem cell transplantation in utero. Proc Natl Acad Sci USA 2005;102:14629–14634.
  24. Krimmel M, Niemann G, Reinert S: Surgical correction of craniosynostosis in malignant osteopetrosis. J Craniofac Surg 2004;15:218–220.
  25. Susani L, Pangrazio A, Sobacchi C, et al: TCIRG1-dependent recessive osteopetrosis: mutation analysis, functional identification of the splicing defects, and in vitro rescue by U1 snRNA. Hum Mutat 2004;24:225–235.
  26. Ilizarov GA, Deviatov AA: [Surgical lengthening of the shin with simultaneous correction of deformities]. Ortop Travmatol Protez 1969;30:32–37.
  27. Matsumoto K, Nakanishi H, Kubo Y, Yokozeki M, Moriyama K: Advances in distraction techniques for craniofacial surgery. J Med Invest 2003;50:17–25.
  28. Talisman R, Hemmy DC, Denny AD: Frontofacial osteotomies, advancement, and remodeling by distraction: an extended application of the technique. J Craniofac Surg 1997;8:308–317.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50